Stock Ratios
Making an investment decision in the stock market involves a certain amount of risk, so it's important to thoroughly review a company's stock before making any decisions. Stock float, number of short positions and outstanding shares are among the many factors an investor should take into account.
profit margin TTM
-43.33%
operating margin TTM
-31.47%
revenue TTM
267.89 Million
revenue per share TTM
1.03$
valuation ratios | |
|---|---|
| pe ratio | -5.36 |
| peg ratio | 0.11 |
| price to book ratio | -7.57 |
| price to sales ratio | 2.88 |
| enterprise value multiple | -33.91 |
| price fair value | -7.57 |
profitability ratios | |
|---|---|
| gross profit margin | 60.08% |
| operating profit margin | -31.47% |
| pretax profit margin | -43.33% |
| net profit margin | -43.33% |
| return on assets | -31.45% |
| return on equity | 172.88% |
| return on capital employed | -36.07% |
liquidity ratio | |
|---|---|
| current ratio | 1.41 |
| quick ratio | 1.21 |
| cash ratio | 0.64 |
efficiency ratio | |
|---|---|
| days of inventory outstanding | 92.72 |
| operating cycle | 171.04 |
| days of payables outstanding | 86.65 |
| cash conversion cycle | 84.38 |
| receivables turnover | 4.66 |
| payables turnover | 4.21 |
| inventory turnover | 3.94 |
debt and solvency ratios | |
|---|---|
| debt ratio | 0.22 |
| debt equity ratio | -0.97 |
| long term debt to capitalization | -3.69 |
| total debt to capitalization | -30.83 |
| interest coverage | -2.77 |
| cash flow to debt ratio | -0.85 |
cash flow ratios | |
|---|---|
| free cash flow per share | -0.19 |
| cash per share | 0.25 |
| operating cash flow per share | -0.19 |
| free cash flow operating cash flow ratio | 1.00 |
| cash flow coverage ratios | -0.85 |
| short term coverage ratios | 0.00 |
| capital expenditure coverage ratio | -20,329.50 |
Frequently Asked Questions
When was the last time Akebia Therapeutics, Inc. (NASDAQ:AKBA) reported earnings?
Akebia Therapeutics, Inc. (AKBA) published its most recent earnings results on 07-11-2024.
What is Akebia Therapeutics, Inc.'s current ROE?
An investor's main concern is the profitability ratios of a company so that they are able to understand how it performs financially. Investors are interested in finding out how effectively a business is using their cash to produce earnings, which is why return on equity (ROE) ratio is important. Akebia Therapeutics, Inc. (NASDAQ:AKBA)'s trailing twelve months ROE is 172.88%.
What are ROA telling us?
The Return on Assets (ROA) ratio measures how profitable a company is relative to its total assets. Akebia Therapeutics, Inc. (AKBA) currently has a ROA of -31.45%. Companies that manage their assets effectively will have greater returns, while those that do so poorly would suffer lower returns.
Where did AKBA's net profit margin stand at?
AKBA reported a profit margin of -43.33% in the last quarter. A company's profit margin, also known as its revenue ratio or gross profit ratio, reflects the amount of revenue that an organization earns compared to its net income. In general, a higher ratio implies greater profit, and vice versa.
What is AKBA's short-term liquidity position?
Apple's current ratio, which measures its ability to pay short-term obligations, was 1.41 in the most recent quarter. The quick ratio stood at 1.21, with a Debt/Eq ratio of -0.97.